Toshihito Ando, Masaki Kondo, Yuriko Asada-Yamada, Miyuka Kawai, Emi Asano-Hayami, Tomohide Hayami, Mikio Motegi, Yohei Ejima, Eriko Nagao, Rina Kasagi, Hiromi Nakai-Shimoda, Saeko Asano, Makoto Kato, Yuichiro Yamada, Emiri Yura-Miura, Takahiro Ishikawa, Yukako Sugiura-Roth, Chika Kojima, Ena Naito, Tatsuhito Himeno, Shin Tsunekawa, Yoshiro Kato, Jiro Nakamura, Hideki Kamiya
AIMS: We aimed to identify patients who would benefit from basal insulin-supported oral therapy (BOT) with a glinide and an α-glucosidase inhibitor (a fixed-dose combination tablet of mitiglinide 10 mg and voglibose 0.2 mg) in Japanese type 2 diabetic patients. METHODS: Patients who were hospitalized to improve hyperglycemia received basal-bolus insulin therapy. After the reduction of glucose toxicity, a 75 g oral glucose tolerance test and a glucagon test were performed...
January 2024: Diabetology International